AbbVie Inc.

Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%

Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone gel 1.62 percent and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.

WWJ Newsradio 950–2013/02/19